TScan Therapeutics

-$0.12 (-3.97%) As of 5:26 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TCRX and other ETFs, options, and stocks.

About TCRX

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts.

CEO
David P. Southwell
Employees
105
Headquarters
Waltham, Massachusetts
Founded
2018

TCRX Key Statistics

Market cap
57.04M
Price-Earnings ratio
—
Dividend yield
—
Average volume
11.43K
High today
$3.21
Low today
$3.02
Open price
$3.11
Volume
2.08K
52 Week high
$14.71
52 Week low
$1.60

TCRX Earnings

-$7.69
-$5.00
-$2.31
$0.38
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 18, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure